MaxCyte (MXCT) Competitors

MaxCyte (NASDAQ:MXCT) and Phreesia (NYSE:PHR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, community ranking, institutional ownership, media sentiment and risk.

Which has more risk & volatility, MXCT or PHR?

MaxCyte has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Phreesia has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.

Does the MarketBeat Community favor MXCT or PHR?

Phreesia received 136 more outperform votes than MaxCyte when rated by MarketBeat users. However, 84.62% of users gave MaxCyte an outperform vote while only 68.06% of users gave Phreesia an outperform vote.

Company	Underperform	Outperform
MaxCyte	Outperform Votes 11 84.62%	Underperform Votes 2 15.38%
Phreesia	Outperform Votes 147 68.06%	Underperform Votes 69 31.94%

Does the media refer more to MXCT or PHR?

In the previous week, Phreesia had 15 more articles in the media than MaxCyte. MarketBeat recorded 16 mentions for Phreesia and 1 mentions for MaxCyte. MaxCyte's average media sentiment score of 1.73 beat Phreesia's score of 0.30 indicating that MaxCyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MaxCyte	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Phreesia	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is MXCT or PHR more profitable?

Phreesia has a net margin of -20.43% compared to MaxCyte's net margin of -78.36%. MaxCyte's return on equity of -16.00% beat Phreesia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-78.36%	-16.00%	-13.93%
Phreesia	-20.43%	-32.78%	-22.37%

Do insiders and institutionals have more ownership in MXCT or PHR?

68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 92.1% of Phreesia shares are owned by institutional investors. 3.0% of MaxCyte shares are owned by company insiders. Comparatively, 5.8% of Phreesia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Do analysts rate MXCT or PHR?

MaxCyte currently has a consensus price target of $9.50, suggesting a potential upside of 146.50%. Phreesia has a consensus price target of $31.15, suggesting a potential upside of 10.49%. Given MaxCyte's higher possible upside, equities research analysts clearly believe MaxCyte is more favorable than Phreesia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Phreesia	0 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger valuation and earnings, MXCT or PHR?

MaxCyte has higher earnings, but lower revenue than Phreesia. Phreesia is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$41.29M	9.88	-$37.92M	-$0.34	-11.33
Phreesia	$356.30M	4.60	-$136.88M	-$1.47	-19.18

Summary

MaxCyte beats Phreesia on 10 of the 17 factors compared between the two stocks.